Slide 1: Uscom AGM 21
PRESENTATION AND UPDATE Uscom AGM 21 ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited October 14, 2021
Slide 2: Summary: Uscom Vision
Summary Uscom Vision SUMMARY “Building a world leading medical technology enterprise combining lifesaving cardiovascular and pulmonary technologies that establish new standards of medical excellence and global academic recognition, with sustainable profits.” Prof. Rob Phillips 2 | Motivated by Visio
Slide 3: Uscom Overview
Uscom Overview ASX Listed Global Vision and Global cardiovascular and pulmonary medical technology Ambitions Sydney, Singapore, Beijing, Budapest, Visionary and innovative Auckland, London, LA. corporate culture Actively pursuing growth and scale Patented Apex Profit and Cash Flow Technologies World
Slide 4: Uscom Snapshot
Uscom Snapshot Uscom is an established medical technology enterprise preparing for a growth inflection with a global footprint and an expanding international network of operations acting as hubs for new distributors 7 Global centres Expanding distribution hubs AUD$ 5.6m annual receipts (FY21) 2 Manu
Slide 5: Digital Technology
Digital Technology Devices addressing diseases responsible for 75% of global mortality SpiroReporter USCOM 1A SpiroAPP Asthma, COPD, OLD and COVID USCOM 1A software Uscom Advanced Haemodynamic APP Heart failure, hypertension, sepsis, fluid Blue Sky Uscom eHealth Ecosystem BP+ Reporter Hypertension,
Slide 6: Global Health
Global Health Uscom - part of the global health solution - WHO Top 10 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 6 | Addressing Global Disease Note: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
Slide 7: Growth Markets
Growth Markets High value technologies in large markets with strong predicted growth $21.6B USD $1.4B USD $1.3B USD 5yr CAGR 4.8% 7yr CAGR 11.2% 5yr CAGR 8.16% USCOM 1A BP+ SpiroSonic AIR The Global Cardiac Monitoring & Cardiac Rhythm The global BP monitoring devices market is $1.4B The global spiro
Slide 8: eHealth Technology
eHealth Technology Frontiers in Digital Health technology USCOM 1A data data USCOM 1A software SpiroReporter Uscom Advanced Haemodynamic APP SpiroSonic APP Blue Sky Uscom eHealth Ecosystem data data Cascade of Revenue AI, Meta Data, BP+ Reporter Licensing, Cloud services, Pay per use, VENTITEST-S Re
Slide 9: eHealth Growth
eHealth Growth eHealth Market forecast to grow at CAGR of 19.4% $250.00 Blue Sky USD 206.3 Billion Uscom eHealth Ecosystem $200.00 USD $Billion • eHealth is a health delivery revolution $150.00 • Uscom is committed to eHealth $100.00 • BlueSky eHealth expected to underwrite USD 59.5 Billion Uscom gr
Slide 10: FY21 Results
FY21 Results 6.00 5.58 Continued Growth 5.00 4.60 Sales, revenue and cash receipts 4.55 4.28 growth, and first ever positive annual 3.85 operating cash flow. 4.00 3.48 First year of cash receipts greater than 3.00 $5.5m despite being a difficult trading year beset by intermittent lockdowns $m AUD an
Slide 11: Sustained Growth
Sustained Growth $0.86m $2.94m $5.58m FY2012 UCM FY2016 UCM FY2021 UCM Total cash receipts Total cash receipts Total cash receipts • Total cash receipts $5.58m, up 21% from $4.60m • First ever cash receipts $6.00 >$5.5m $5.00 5.46 • 9 year total cash receipts trend growth 4.6 $4.00 535% total incr
Slide 12: New Regulatory
New Regulatory New approvals = new sales = new revenue All Uscom devices received new approvals in major jurisdictions in FY21 12 | Regulatory News
Slide 13: Global Approvals
Global Approvals 7 New Approvals for FY22 up from 5 (up 140%) Regions Approvals China SE Asia Euro US Russia ROW USCOM ✓ 1A 2021 ✓ ✓ ✓ ✓ ✓ ✓ 2022 China Pending SE Asia ✓ ✓ ✓ ✓ ✓ ✓ Europe US ✓ New Approvals Russia 13 | New Products and New Regions
Slide 14: Regulatory Lift
Regulatory Lift 7 new approvals for USCOM 1A, BP+, SpiroSonic for FY22 14 | More Products, Distributors, Sales and Revenue
Slide 15: USCOM 1A
USCOM 1A • 1500th USCOM 1A Manufactured • ~$30m USD • >400 peer reviewed papers • Life saving, standard of care • COVID, Sepsis, heart failure, fluid, hypertension, preeclampsia • Neonates, children and adults • Installed in top hospitals worldwide 15 | Standard of Care USCOM 1A
Slide 16: COVID and Uscom
COVID and Uscom COVID – USCOM 1A • COVID - Lung virus which attacks cardiovascular system • Patients mostly die from cardiovascular failure • USCOM 1A best device for rapid CV monitoring and therapy • USCOM 1 – recommended by China NHMC for severe COVID treatment • >50 new China infectious disease c
Slide 17: SpiroSonic AIR
SpiroSonic AIR “Hospital in Home” – Asthma, COVID, COPD and OLD The SpiroSonic AIR Cycle – a wireless connection of data, information, diagnosis and reports generating a cascade of revenue eHealth Revenue Cascade • Device sale • APP Sale • Software sale • Cloud storage - Big data • AI analysis • Cli
Slide 18: VentiTest
VentiTest The SpiroSonic VentiTest is a patent protected digital multi-path ultrasonic ventilator testing and calibration solution which incorporates: Low resistance High resolution bi-directional digital multi- Pressure module to control path acoustic flow piezoresistive monolithic silicon monitor
Slide 19: Global Specialisation
Global Specialisation Transitioning to a complex global organisation requires specialised operational divisions within the company to support efficient growth and expansion Finance and Management Marketing, Sales and Each region accounts and reports Distribution independently and to HQ Global coordi
Slide 20: New Technology R&D
New Technology R&D World leading science Invasive validation of BP+ waveforms BP+ Reporter Hypertension, vascular health 20 | Life Saving Science
Slide 21: China Recognition
China Recognition “Building a Global Business” Uscom China Listed as China National High Uscom China ranked AAA Credit Enterprise by Technology Enterprise by PRC Ministry of China Credit Enterprise Publicity Network Science and Technology 21 | China Recognition for Excellence
Slide 22: Regional Strategy
Regional Strategy Australia China Hungary Singapore UK US Uscom China More, bigger and better distribution, prepare BP+ and SpiroSonic marketing and distribution, and develop domestic manufacture Uscom Europe Growing manufacturing capacity to meet demand and increasing distribution and sales for USC
Slide 23: Achievements and Plans
Achievements and Plans A transformational year for Uscom Limited FY21 – Performance and Investment Results Operations Operating Cash Positive 3 new Product Approvals China Profit 2 Approvals Pending Europe Profit 1500th 1A Unit Sale Total Receipts $5.6m Global Distribution Growth Cash on hand New Re
Slide 24: Growth and Profit
Growth and Profit The year ahead FY22 - Growth & Profit. Growth & Profit We have invested in the future, and our next steps to are to combine our vision, Products Sales culture, people, organisation, products, sales and global strategy to deliver growth and sustainable profit; Global Strategy Organi
Slide 25: Summary
Summary FY21 – Performance and Investment “FY21 was a very good year for Uscom, with continued SUMMARY Strong revenue growth, Operating cash flow positivity, China profit, Europe profit and Multiple device approvals.” FY22 – Growth and Profit “We plan expansion and growth, with new manufacturing – g
Slide 26: Thank You
PRESENTATION AND UPDATE Thank You ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited October 14, 2021
Slide 27: Corporate Responsibility
Corporate Responsibility Uscom supports the Australian Wildlife Conservancy. in the last 15 years Australia's threatened species list has increased by 36%. 87% of our mammal species, 93% of reptiles, 94% of frogs and 45% of our bird species are found only in Australia. AWC is committed to reversing